Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;82(8):941-947.
doi: 10.1007/s40265-022-01727-x.

Olipudase Alfa: First Approval

Susan J Keam  1
Affiliations
Review

Olipudase Alfa: First Approval

Susan J Keam. Drugs. 2022 Jun.

Abstract

Olipudase alfa (XENPOZYME®) is a recombinant human acid sphingomyelinase that has been developed by Sanofi, for the treatment of acid sphingomyelinase deficiency (ASMD). Olipudase alfa catalyses the hydrolysis of sphingomyelin accumulated in hepatocytes and in mononuclear-macrophage cells, such as the lungs, liver, spleen, kidneys and bone marrow. Olipudase alfa was approved in Japan under the SAKIGAKE designation on 28 March 2022 for use in adult and paediatric patients with non-CNS manifestations of ASMD and has received a positive Committee for Medicinal Products for Human Use opinion in the EU. Regulatory review in the USA is underway. This article summarizes the milestones in the development of olipudase alfa leading to this first approval for the treatment of patients with ASMD.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McGovern MM, Dionisi-Vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19(9):967–74. - DOI
    1. Wasserstein M, Dionisi-Vici C, Giugliani R, et al. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Mol Genet Metab. 2019;126(2):98–105. - DOI
    1. Sanofi. Xenpozyme®(olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency [media release]. 28 Mar 2022. http://www.sanofi.com .
    1. Sanofi. Olipudase alfa (XENPOZYME®) IV infusion: Japanese prescribing information. 2022. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_39594A9D1022_1_01 . Accessed 31 Mar 2022
    1. Sanofi. CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD [media release]. 20 May 2022. https://www.sanofi.com .

LinkOut - more resources